Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04576936 · ClinicalTrials.gov registry record · NA
AIRVO Device Intervention for Moderate to Severe COPD
A NA study, sponsored by Renown Health.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT04576936 is a NA study that was terminated before completion, run by Renown Health. The registered enrollment target is 1 participants.
The verdict
NCT04576936, a NA study, was terminated before completion, sponsored by Renown Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an open (non-blinded), single-arm, clinical trial to assess the efficacy of daily use of a high-flow nasal cannula (HFNC) device in patients with moderate to severe COPD, in addition to standard care, in reducing the amount of COPD exacerbations over a one-year period. Once enrolled in the study, all subjects will be asked to undergo a baseline walking test to measure pulmonary function (6MWT), verify their personal and medical history (demographics), as well as fill in some questionnaires regarding their COPD and its symptoms (SGRQ-C, CAT). All subjects will then receive their own AIRVO2 device, as well as training and instructions on how to use the device at home. Subjects will use the MyAIRVO2 device daily for the following 12 months. Follow-up visits will occur five times over the 12-month study period and will be similar to the baseline visit. Additional data will be collected by the study team for each subject from their electronic medical record during the 12-month study enrollment period. Only information regarding COPD-related medical and/or pharmacy costs, specifically to measure the amount of COPD exacerbations experienced by each subject, will be reviewed and recorded.
Interventions
- OTHER AIRVO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2021-12-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04576936
The ClinicalTrials.gov registry entry for NCT04576936 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Renown Health, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AIRVO is the first listed.
NCT04576936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04576936 about?
NCT04576936 is a clinical study titled "AIRVO Device Intervention for Moderate to Severe COPD". This is an open (non-blinded), single-arm, clinical trial to assess the efficacy of daily use of a high-flow nasal cannula (HFNC) device in patients with moderate to severe COPD, in addition to standard care, in reducing the amount of COPD exacerbations over a one-year period. Once enrolled in the s...
What is the current status of trial NCT04576936?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2021-01-15. Estimated completion is 2021-12-28.
What interventions are being tested in trial NCT04576936?
The interventions under investigation include: AIRVO (OTHER).
Who is sponsoring clinical trial NCT04576936?
This trial is sponsored by Renown Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.